About Ralph E. Holsworth, Jr.

Mission Statement


My mission is to utilize its proprietary technologies to develop ethical pharmaceuticals to better the lives of patients worldwide who are suffering from some of the most prevalent diseases and conditions affecting industrial countries, cardiovascular disease.  Specifically, I am researching and developing novel pharmaceutical agents that decrease whole blood viscosity in humans and animals, the common denominator of over 300 independent cardiac risk factors.  As the most sensitive and earliest biomarker to identifying cardiovascular disease, I provide a novel class of preventative strategies and interventional agents to slow and reverse atherogenesis.  As the founding physician/research, Dr. Ralph E. Holsworth, Jr., I have named this new class of medications as “anti-viscogenic” agents.   By targeting a central modality of cardiovascular pathophysiology, my goal is to provide the first intervention at conception of disease, to minimize mortality and morbidity, negatively impacting human well-being and productivity and requiring the significant utilization of finite, medical resources. Applications under way or planned include cardiovascular disease, recovery from surgery and other medical interventions, emergency medicine, and other conditions affecting heart or skeletal muscle perfusion and microcirculation.

Who Am I

Dr. Ralph E. Holsworth, Jr., D.O. is a board-certified physician in Family Medicine who is internationally known through his research and publications in the area of enzyme enhanced medical treatment. Dr. Holsworth is a former commissioned officer in the United States Public Health Service. He is also an international guest speaker at medical conferences and conventions.

As a U.S. Navy nuclear propulsion plant operator, Dr. Holsworth completed two years of intensive nuclear physics, corrosion chemistry and fluid dynamics. He earned his Bachelor of Science degree in Geochemistry at the University of Texas in 1985 and his Doctorate of Osteopathy in 1997 from the College of Osteopathic Medicine in Kansas City, Missouri. He has been practicing as a family medicine physician with an emphasis on functional and integrative medicine since graduation. His specific interests are in systemic enzyme therapy where he has been involved in clinical and laboratory research for over a decade. His medical licensing is through the State of Colorado.

His background includes service as a medical staff officer for the U.S. Public Health Services. He also was an Honorary Professor in the Department of Biology at the University of Colorado in 2001. Further professional experiences include participation in the review of clinical trials of Wormwood Treatment for Cancer in 1998 at the National Academy of Science in Kazakhstan. In 1997, Dr. Holsworth worked as a research assistant in the area of Oral Systemic Enzymes as Adjuvant Cancer Treatment at The Cancer Treatment Center of Tulsa in Oklahoma.

His recent research with the USC’s Keck School of Medicine demonstrated nattokinase’s therapeutic ability to lower human blood viscosity (a “true blood-thinner”) and to prevent the aggregation of red blood cells and platelets. Currents studies involve nattokinase’s enhancement of fibrinolysis and drug delivery mechanisms to potentiate nattokinase’s pharmokinectics.

Professional memberships include the American College of Osteopathic Family Physicians, Japan Nattokinase Research Association, and the Oxygen Society. He is an editorial board member at the Journal of Applied Clinical Thrombosis/Hemostasis and a Fellow of the International Academy of Clinical and Applied Thrombosis/Hemostasis. Dr. Holsworth is also listed in the Cambridge WHO’S WHO Honors Edition 2007-2008.

© 2019, Dr. Ralph Holsworth, All Rights Reserved - Website design by WSB Computer Services, Inc.